Methylation is vital in many biological processes, and potent and specific inhibitors of methyltransferases are valuable tools in understanding these processes. Some positive clinical and preclinical results from DMA methyltransferase inhibitors indicate the potential use of these inhibitors in cancer therapy. In this proposal, we intend to develop a fluorescence polarization assay which is non-radioactive and amenable to high throughput screening. This will greatly facilitate the discovery of novel inhibitors of methyltransferases by high throughput screening. These inhibitors will be not only valuable research tools to study the large family of important enzymes but also initial leads to develop future drugs for cancer and other diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21NS053726-01
Application #
7021206
Study Section
Special Emphasis Panel (ZNS1-SRB-G (01))
Program Officer
Scheideler, Mark A
Project Start
2005-09-30
Project End
2006-07-31
Budget Start
2005-09-30
Budget End
2006-07-31
Support Year
1
Fiscal Year
2005
Total Cost
$51,696
Indirect Cost
Name
University of Kansas Lawrence
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
076248616
City
Lawrence
State
KS
Country
United States
Zip Code
66045